In the group of patients that did not receive mAb, 6/9 had Spike/ACE2-blocking antibodies above threshold, whereas all but one patient that received mAb treatment had detectable Spike/ACE2-blocking antibodies at <30 days after infection. Here, ACE2 is linked to infection.